Tonix Pharmaceuticals Holding Forum: Community User: StefanN19

Bald kommen wir auf die 3- 3.5$ schon. Wie Stefan sagt...Monatschart sind blendent aus .

Denke das ist ne super Rendite

Scgau dir doch mal den monatschart an

Warum läuft es nicht Plankton

Ich überlege mit einzusteigen. Was meint ihr? Wird bald mehr kommen? Bei TR sahen Analysten 2.6 voraus

Ich bleib jetzt mal drinnen, auch wenn's nicht bombastisch läuft

📍

👍

Wachstum in kleinen Schritten ist mir lieber als dieser steile Anstieg durch einen Hype mit anschließendem Fall in den Keller.

Strong long here 😄

👀

Danke

https://www.accesswire.com/629598/NewtoTheStreets-New-to-The-Streets-Newsmax-Sunday-930AM-EST-lineup-features-Tonix-Pharmaceuticals-Holding-Corp-Nextech-AR-Winston-Gold-and-NativeCoin

Hallo zusammen.was wird den genau bei Tonix am Dienstag angekündigt, da müsste doch irgendwas sein oder nicht?

WDP Pharmaceuticals auch ein guter Kanditat mit Potential nach oben

Die Tonix Pharmaceuticals Holding Corp. möchte Lehren aus Tuberkulose und Pocken ziehen, um ihre Zukunft bei Infektionskrankheiten zu steuern. Das **** entwickelt einen intradermalen Hauttest wie den für TB zur Messung der T-Zell-Immunität gegen SARS-CoV-2, das Virus, das COVID-19 verursacht. Es sind auch drei Impfstoffe für COVID-19 in der Entwicklung, die auf Pocken beruhen, wahrscheinlich der Form von Vaccinia, die Edward Jenner zur Herstellung des Pockenimpfstoffs verwendet. Die Aktien von Tonix aus Chatham, NJ, stiegen um 22%, nachdem die Entwicklung des TNX-2100-Hauttests bekannt wurde. Das **** meldete außerdem ein Aktienangebot von rund 58,3 Millionen Stammaktien zu 1,20 USD je Aktie. Das Angebot sollte 70 Millionen US-Dollar vor Gebühren und Kosten einbringen, die das **** zur Finanzierung der weiteren Bewertung des Tests, mehrerer Impfstoffkandidaten und anderer klinischer Studien verwenden will. "Wir glauben, dass TNX-2100 das Potenzial hat, die T-Zell-Immunität gegen [SARS-] CoV-2 zu messen, und daher als Hilfe für die COVID-19-Diagnose zur Unterstützung der Patientenversorgung, der Überwachung der öffentlichen Gesundheit und von Impfstoffversuchen dient", sagte Tonix CEO Seth Lederman. Das **** hat von der US-amerikanischen FDA eine schriftliche Antwort erhalten, die es als „bisher positiv“ bezeichnete, auf ein Meeting-Paket für ein neues Arzneimittel (IND) vor der Untersuchung, das den diagnostischen Hauttest beschreibt, auf den die verzögerte Überempfindlichkeitsreaktion gemessen wird SARS-CoV-2. “Based on guidance provided by FDA in their written response, we believe we have the information necessary to respond to queries and file the IND application in the second quarter of 2021,” said Herbert Harris, Ton’s executive vice president for translational medicine. The company expects to start trials of the test in the second half of 2021. The importance of T-cell immunity The new test could simplify measurement of T-cell immunity, which lasts considerably longer than antibody-based immunity. While antibodies to many viral diseases wanes in six months or so, T-cell immunity for some infections lasts a lifetime. Notably, the level of antibody response in individuals known to have been infected with SARS-CoV-2 and recovered varies from quite robust to undetectable. A T-cell test would illuminate the nature of immune responses, particularly in people without discernable antibodies. Currently, no standardized laboratory tests measure T-cell immune response to the novel coronavirus and the ones available “using intracellular cytokine staining are only done in advanced, highly specialized labs,” Lederman told BioWorld. “Those tests can’t be standardized ... but they have shown us that T-cell immunity is important and that people with strong T-cell response are less likely to go to the hospital.” In comparison, the highest levels of neutralizing antibodies are found in patients who die on respirators, he noted. The test could be useful as a biomarker for immunity and to stratify participants in vaccine trials, so that individuals who started with some natural immunity based on previous infection are not included in analyses with people who had no immunity prior to vaccination. In addition, the test would help measure response to vaccination and assess durability of protection. “The skin test could be used after vaccinations to see if they were successful. If someone didn’t have a good response, you would revaccinate,” Lederman said. If trials support the test, it could be used by clinicians, patients, employers, long-term care facilities and public health officials to confirm immunity to SARS-CoV-2 quickly and inexpensively. Given that the durability of the vaccines currently approved and in development are unknown because the virus has only been identified for just over a year, a reliable and rapid way to test persistence of immunity will be a tool for vaccine developers and protection of public health. The test The Tonix skin test for T-cell immunity would work like the Mantoux test for TB, pictured here. Credit: Wikimedia TNX-2100 uses a procedure similar to the Mantoux purified protein derivative test for tuberculosis. A small amount of an antigen is inserted intradermally on the underside of the forearm with a **** needle. Within 48 hours, individuals with T-cell memory develop hard red, raised lesions that can be measured with a take-home device. The Tonix test uses three synthetic peptides (TNX-2110, TNX-2120, and TNX-2130) that correlate to different protein components of SARS-CoV-2. TNX-2110 represents multiple proteins from the virus, while TNX-2120 represents the spike protein and TNX-2130 non-spike proteins. Each of the three synthetic peptides would be injected in a different part of the arm. Individuals exposed to or infected by SARS-CoV-2 would be expected to develop a red wheal in all three locations. Someone successfully immunized with one of the current vaccines, but not previously exposed, would see a reaction only to TNX-2120 as those vaccine only encode the spike protein. The diameter of the lesion indicates the amount of T-cell immunity to the test peptides. “It takes the whole parameter of T-cell immunity out of specialized labs,” Lederman explained. “The test can be administered by trained individuals less skilled than a nurse and patients can take a picture on their phone showing the size of the lesion with a paper ruler.” Article reprints BioWorld MedTechCoronavirusDiagnosticsU.S. KEYWORDS COVID-19 SARS-CoV-2 T-cell immunity T-cell response TNX-2100 Tonix Pharmaceuticals Holding Corp. tuberculosis Annette Boyle Gns Healthcare scores $23M in series D funding round More from this author Popular Stories Free access to BioWorld coronavirus articles BioWorld The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are... Senioren mit Holzpuzzle Cassava’s simufilam improves AD patients’ cognition, behavior BioWorld Today's news in brief BioWorld BioWorld briefs for Feb. 12. Vaxart COVID-19 Impfstofftabletten Vaxart shares shaken despite apparently positive early data for oral COVID-19 vaccine BioWorld IPO-Geld Lucira Health launches $153M IPO BioWorld MedTech cortellis ad BioWorld Premium Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription. Subscribe BioWorld Today's news Analysis and data insight Clinical Data Snapshots Deals and M&A Financings Newco news Opinion Regulatory Science BioWorld MedTech Today's news Clinical Data Snapshots Deals and M&A Financings Newco news Opinion Regulatory Science BioWorld Asia Today's news Analysis and data insight Australia China Clinical Deals and M&A Financings Newco news Regulatory Science BioWorld Science About Archives Today's news Search BioWorld Science More About Archives Nachdrucke und Berechtigungen von Artikeln Kontaktiere uns Cookie-Richtlinie Urheberrechtshinweis Datenmethodik Datenschutz-Bestimmungen Teilen Sie Ihre Neuigkeiten mit BioWorld Mitarbeiter Nutzungsbedingungen Folge uns Copyright © 2021. Alle Rechte vorbehalten. Design, CMS, Hosting & Webentwicklung :: ePublishing